Cassava Sciences Inc vs iShares Silver Trust — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while iShares Silver Trust trades at $59.75. The key difference: iShares Silver Trust is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SLV | |
|---|---|---|
Market Cap | $47.75M | — |
Sector | Health | — |
52-Week High | $4.64 | $105.57 |
52-Week Low | $0.87 | $33.89 |
Enterprise Value | -$34.93M | — |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
SLV (iShares Silver Trust) trades at $57.50, up 2.95% with a bullish technical signal supported by moving averages. The ETF provides direct exposure to physical silver, which has seen volatile trading after a 50% decline from early 2026 highs. Recent price action shows silver rebounding amid Fed policy uncertainty and strong industrial demand fundamentals.
Silver's outlook remains compelling due to constrained supply and growing industrial demand, though high volatility and Fed policy sensitivity pose risks. The current technical setup suggests potential for continued upside if silver maintains support above $56, with resistance near $59.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →